课题基金 / 基金详情

PATHOGENESIS OF CANCER--ROLE OF EGF RECEPTOR ENDOCYTOSIS

PATHOGENESIS OF CANCER--ROLE OF EGF RECEPTOR ENDOCYTOSIS
癌症发病机制--EGF受体内吞作用的作用
批准号:
6228776
负责人:
ALEXANDER D SORKIN
金额:
$23.78万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-01-01 至 2005-12-31

项目摘要

项目成果

ALEXANDER D SORKIN的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自研究者摘要)生长因子受体 在细胞增殖、分化和调节性死亡中发挥核心作用。 这些受体的特定信号调节不良是一个重要的 癌症发病机制和进展。表皮生长因子 受体(EGFR)和ErbB酪氨酸激酶家族的其他成员是重要的 在人肿瘤形成中,特别是在乳腺、子宫颈、卵巢、胃、膀胱 和肺癌,以及神经母细胞瘤/胶质母细胞瘤。这些受体具有 成为癌症预防和治疗的主要目标。EGFR已被用于 作为几种类型癌症的预后标志物,EGFR的抗体 作为一种抗癌疗法进行了测试。然而,抗体的一般局限性 治疗和EGFR在正常组织中的存在提出了新的需求, 特异性抑制肿瘤细胞中EGFR的方法以及将EGFR用作 癌症不同阶段的标志物。 配体对EGFR的激活通常导致快速的内吞作用, EGFR的下调。通过下调EGFRs,内吞作用起到了 EGFR信号传导的持续时间和强度的主要调节因子。的 这一过程的限速步骤是受体内化, 网格蛋白包被的凹坑相反, EGFR在过表达EGFR的许多类型的癌细胞中是可忽略的。我们 假设EGFR通过被膜小凹的内吞途径是饱和的 因为它的能力受到特定蛋白质含量低的限制 负责将激活的EGFR募集到被膜小凹中。的目标 建议是查明这些涂层坑“招募者”, 表征它们如何参与癌细胞中EGFR的下调。 CPR的功能表征将使用新的 我们已经开发的活细胞中的蛋白质-蛋白质相互作用分析。一 长期目标是确定肿瘤中CPRs的表达和调控 其中EGFR在转化中起重要作用。我们的预测是, 在正常和肿瘤细胞中差异表达。例如,低水平 CPRs在癌组织中的表达可能是其维持的主要原因 这些细胞中有大量激活的EGFR。因此,CPR很可能是 癌症预防和治疗的重要新靶点。心肺复苏分子将 在良性宫颈粘膜、鳞状上皮内病变和 鳞状细胞癌,以确定CPR分析是否可以发挥作用, 确定预后和指导潜在患者的治疗 宫颈粘膜的癌前病变或恶性病变。
英文摘要
DESCRIPTION: (Adapted from the investigator's abstract) Growth factor receptors play a central role in cell proliferation, differentiation and regulated death. Poor regulation of specific signals from these receptors is an important mechanism of cancer pathogenesis and progression. The epidermal growth factor receptor (EGFR) and other members of ErbB tyrosine kinase family are important in human neoplasia, particularly in breast, cervical, ovary, stomach, bladder and lung carcinomas, and in neuroblastomas/glioblastomas. These receptors have become major targets for cancer prevention and therapy. The EGFR has been used as a prognostic marker in several types of cancer, and an antibody to EGFRs has been tested as an anti-cancer therapy. However, general limitations of antibody therapy and the presence of EGFRs in normal tissue pose a need for new approaches to specifically inhibit EGFRs in tumor cells and to use the EGFR as a marker of the various stages of cancer. Activation of EGFRs by ligand normally results in the rapid endocytosis and down-regulation of EGFRs. By down-regulating EGFRs, endocytosis serves as the major regulator of the duration and intensity of signaling by the EGFR. The rate-limiting step of this process is receptor internalization via clathrin-coated pits. In contrast, the internalization and down-regulation of EGFRs is negligible in many types of cancer cells that overexpress EGFRs. We hypothesize that the endocytic pathway of EGFRs via coated pits is saturable because its capacity is limited by the low amount of specific proteins responsible for recruitment of activated EGFRs into coated pits. The goal of the proposal is to identify these coated pit "recruiters" (CPRs) and to characterize how they participate in down-regulation of EGFR in cancer cells. The functional characterization of CPRs will be accomplished using novel protein-protein interaction assays in living cells that we have developed. A longer-term goal is to define the expression and regulation of CPRs in tumors where EGFR is important in the transformation. Our prediction is that CPRs are differentially expressed in normal and tumor cells. For instance, low levels of expression of CPRs in cancer tissue may be a primary reason of the maintenance of large amounts of activated EGFR in these cells. Therefore, CPRs may well be important new targets for cancer prevention and therapy. CPR molecules will be evaluated in benign cervical mucosa, squamous intraepithelial lesions, and squamous cell carcinomas to determine if CPR analysis could play a role in the determination of prognosis and in guiding therapy of patients with potentially premalignant or malignant lesions of the cervical mucosa.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EGF Receptor Endocytosis: Mechanisms and Role in Signaling
Admin Supplement - Pathogenesis of Cancer - Role of EGF Receptor Endocytos
Administrative Supplement-Signaling by the EGF Receptor from Endosomes
Signaling by the EGF Receptor from Endosomes
海外基金